MAM
RVCJ pioneering the future of Meme marketing in India
Mumbai: RVCJ, one of the media and entertainment companies, has been instrumental in shaping the meme marketing landscape in the country. With its unique approach to humour and witty content, RVCJ has captured the attention of millions of social media users across India. As we look towards the future of meme marketing in India, it’s impossible to ignore the role that RVCJ will continue to play.
According to the RVCJ Media co-founder & CRO Aziz Khan, ‘ The ability to stay relevant and connect with its audience will be key to its success in the years to come. With the rise of newer platforms and changing user behaviour, RVCJ has already started exploring new formats and mediums to reach its audience. From short-form videos to interactive content, RVCJ is constantly evolving to stay ahead of the curve.
Beyond 2024, RVCJ will likely continue to lead the meme marketing landscape in India. With its strong brand identity and deep understanding of its audience, RVCJ is well-positioned to take advantage of the growing demand for humour and relatable content. By leveraging its expertise and creativity, RVCJ will allegedly continue to shape the future of meme marketing in India and beyond.
RVCJ’s success story in India’s meme marketing landscape can be attributed to its unique and refreshing approach to humour and content creation. With millions of social media users hooked on to their platform, RVCJ has become a household name in the world of memes and entertainment. However, experts believe that the company must continue to innovate and adapt to the changing market trends to maintain its position in the industry.
The key to RVCJ’s future success lies in its ability to stay relevant and resonate with its audience. RVCJ has shown that it is willing to evolve and stay ahead of the curve by exploring new formats and mediums such as short-form videos and interactive content. This adaptability will be crucial in the coming years as the market continues to change and new platforms emerge.
Looking forward, RVCJ is poised to continue to serve the meme marketing landscape in India. With its strong brand identity and deep understanding of its audience, the company is well-positioned to take advantage of the increasing demand for relatable and humorous content. By leveraging their expertise and creativity, RVCJ will undoubtedly shape the future of meme marketing not only in India but also beyond.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
